ライフサイエンスコーパス: ATV

1 ATV alone or in combination with PIO markedly augmented

2 ATV and PIO at 5 and 10 mg x kg(-1) . d(-1) significantl

3 ATV as an adjunct to SRP can provide a new direction in

4 ATV decreased bone loss, reduced MPO, TNF-alpha, IL-1bet

5 ATV has a distinct resistance profile relative to other

6 ATV particles in late and recycling endosome compartment

7 ATV reduced inflammation, oxidative stress, and bone los

8 ATV reduced RANKL and DKK-1 and increased OPG, WNT10b, a

9 ATV was found in biliary calculi in 8 of 11 cases: infra

10 ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-

11 ATV+DDI+FTC had inferior efficacy and is not recommended

12 ATV, however, retained sensitivity to perforin-mediated

13 ATV/r did not significantly affect boceprevir exposure,

14 ATV:TREM2 treatment in AD model mice improved energy met

15 g(-1) x d(-1); or PIO 10 mg x kg(-1) x d(-1)+ATV 10 mg x kg(-1) x d(-1).

16 s received water; PIO 10 mg x kg(-1) x d(-1)+ATV 10 mg x kg(-1) x d(-1); PIO+ATV and valdecoxib, a se

17 water; PIO 2, 5, or 10 mg x kg(-1) x d(-1); ATV 2, 5, or 10 mg x kg(-1) x d(-1); or PIO 10 mg x kg(-

18 into two treatment groups: 1) SRP plus 1.2% ATV and 2) SRP plus placebo.

19 PRF + 1.2% ATV and PRF alone showed significantly greater PD reduct

20 zed into two treatment groups: SRP plus 1.2% ATV and SRP plus placebo gel.

21 is to investigate the effectiveness of 1.2% ATV as an adjunct to scaling and root planing (SRP) in t

22 Thus, 1.2% ATV failed to augment the regenerative potential of PRF

23 1.2% RSV gel (group 2); and 3) SRP with 1.2% ATV gel (group 3).

24 nd compare the efficacy of 1.2% RSV and 1.2% ATV gel local drug delivery (LDD) and redelivery systems

25 o evaluate combined efficacy of PRF and 1.2% ATV gel with open flap debridement (OFD) in treatment of

26 ims to explore efficacy of 1.2% RSV and 1.2% ATV gels as a local drug delivery and redelivery system

27 r clinico-radiographic improvement than 1.2% ATV or placebo gels as adjunct to mechanical periodontal

28 Furthermore, PRF + 1.2% ATV showed a similar percentage radiographic defect dept

29 PRF + 1.2% ATV showed similar improvements in clinical parameters w

30 t with SRP followed by LDD of 1.2% RSV, 1.2% ATV, or placebo gel.

31 ups: 1) OFD with PRF; 2) OFD with PRF + 1.2% ATV; and 3) OFD alone.

32 roups: 1) naive; 2) EP; 3) GIOP + EP; and 4) ATV.

33 h the radiotracer [(64)Cu]Cu-NODAGA-ATV:4D9 (ATV is antibody transport vehicle).

34 nsferrin receptor, peripherally administered ATV(CD98hc) demonstrates differentiated brain delivery w

35 After ATV therapy, there was a significant decrease in LDL con

36 d by A. mexicanum as early as 24 hours after ATV infection.

37 .3), then TFV (3.52, 95% CI, 2.27-5.48), and ATV (2.39, 95% CI, 1.69-3.38).

38 CSCs can enhance CRCC by secreting IL-6 and ATV may interfere the whole regulation.

39 tions at residue 50 affect how APV, DRV, and ATV bind the protease with altered van der Waals interac

40 To explain how APV, DRV, and ATV susceptibility are influenced by mutations at residu

41 BC/3TC and TDF/FTC groups (combining EFV and ATV/r arms; median change, -341 [interquartile range, -8

42 Groups GIOP + EP and ATV received 7 mg/kg dexamethasone intramuscularly once

43 Groups EP, GIOP + EP, and ATV were submitted to EP by ligature around the maxillar

44 mg; part B subjects receiving GSK3532795 and ATV +/- RTV achieved similar declines to those receiving

45 l fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 mg/100 mg) for 28 days.

46 Both PIO and ATV increase myocardial levels of 15-epi-LXA4, a mediato

47 antiinflammatory properties of both PIO and ATV.

48 B-100 pool size (PS) in both the placebo and ATV groups.

49 tion containing a 1:1 molar ratio of RTV and ATV achieved only 50% of the supersaturation attained by

50 In the brain, ATV(TfR) and ATV(CD98hc) achieve enhanced exposure and parenchymal di

51 In contrast, ATV(TfR) and ATV(CD98hc) exhibit broad and unique parenchymal cell-ty

52 hc antibody transport vehicles (ATV(TfR) and ATV(CD98hc)) compared to control IgG.

53 sing the Aptima Trichomonas vaginalis assay (ATV; Gen-Probe) and the prevalence of Chlamydia trachoma

54 GenProbe Aptima Trichomonas vaginalis assay; ATV) for T. vaginalis were compared with the Affirm VPII

55 Atazanavir (ATV) is a once-daily human immunodeficiency virus (HIV)

56 )-infected patients receiving an atazanavir (ATV)-based antiretroviral regimen developed complicated

57 RTV in the bidirectional TVR and atazanavir (ATV) interactions.

58 Ritonavir (RTV) and atazanavir (ATV) were co-formulated with polyvinylpyrrolidone to pro

59 ricitabine and ritonavir-boosted atazanavir (ATV) underwent serial paired cervicovaginal and plasma s

60 and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).

61 e therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside rever

62 is observed in patients failing atazanavir (ATV) therapy.

63 d then received PI/r as follows: atazanavir (ATV) 300 mg once daily, lopinavir (LPV) 400 mg twice dai

64 ontaining the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogenization.

65 r (RTV) as a pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)/tenofovir d

66 V) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

67 ed to darunavir (DRV) but not to atazanavir (ATV).

68 80 mg GSK3532795 once daily with atazanavir (ATV) with or without (+/-) ritonavir (RTV) or standard o

69 ine [FTC], and ritonavir-boosted atazanavir [ATV]) with suppressed plasma virus loads, blood and cerv

70 Atorvastatin (ATV) has shown pleiotropic effects on bone tissue, and o

71 Atorvastatin (ATV) is a specific competitive inhibitor of 3-hydroxy-2-

72 evaluate effectiveness of 1.2% atorvastatin (ATV) gel, as an adjunct to scaling and root planing (SRP

73 Rosuvastatin (RSV) and atorvastatin (ATV) are known to inhibit osteoclastic bone resorption a

74 Rosuvastatin (RSV) and atorvastatin (ATV) have shown bone stimulatory and anti-inflammatory e

75 tion platelet concentrate, and atorvastatin (ATV), a potent member of the statin group, are known to

76 antial cholesterol, we applied atorvastatin (ATV) to Madin-Darby Canine Kidney cells before infecting

77 ther placebo (n = 10) or 20 mg atorvastatin (ATV) (n = 29) for 4 weeks.

78 Patients received 80 mg atorvastatin (ATV) or matching placebo for a 12-week treatment period

79 ent studies have reported that atorvastatin (ATV) may change the dynamic of cognitive impairment in a

80 We investigated whether atorvastatin (ATV) and pioglitazone (PIO) increase the myocardial cont

81 important role in the emergence of ATV, (b) ATV bearing a Fas-resistant phenotype was a chief conseq

82 jective was to evaluate associations between ATV or DRV exposures and the risk of myocardial infarcti

83 There were no differences between ATV and placebo with regard to the surrogate markers mea

84 ven when brain exposures are matched between ATV and control IgG in bulk tissue.

85 CV)/HIV-coinfected patients on a RTV-boosted ATV-based (ATVr) antiretroviral regimen (300/100 mg ever

86 For both ATV and TFV, FGT:plasma was significantly lower in parti

87 In the brain, ATV(TfR) and ATV(CD98hc) achieve enhanced exposure and p

88 CONTEXT: Atorvastatin calcium (ATV), a cholesterol-lowering agent, suffers from poor sy

89 new study presents a therapeutic candidate, ATV:TREM2, a TREM2 activating antibody engineered with a

90 thematical model to a single or combination (ATV+TZB) therapy used in the experiments to demonstrate

91 Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a median follow-up of

92 did not significantly differ for concurrent ATV/r for 750 mg BID or 1500 mg BID when compared to the

93 In contrast, ATV(TfR) and ATV(CD98hc) exhibit broad and unique parenc

94 were drawn from the injury survey; controls (ATV drivers who had not been injured) were drawn from th

95 Locally delivered ATV was found to be effective in treatment of intrabony

96 substitution were growth impaired, displayed ATV-specific resistance, and had increased susceptibilit

97 navir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-

98 ing a new nanovesicular system encapsulating ATV for its delivery via the transdermal route.

99 (90% confidence interval [CI], .55-.78) for ATV/r; 0.66 (90% CI, .60-.72) for LPV/r, and 0.56 (90% C

100 is compensated for by enhanced enthalpy for ATV binding to I50V variants and APV binding to I50L var

101 sectional study of patients hospitalized for ATV injuries in Canada, youths aged 16 to 20 years and a

102 position for APV/DRV and the P2 position for ATV.

103 Furthermore, ATV group sites presented with a significantly greater p

104 Furthermore, ATV that survived CTL adoptive immunotherapy displayed a

105 Group ATV received 27 mg/kg ATV orally, and the others receive

106 The results revealed high ATV entrapment efficiency (EE%) ranging from 55.62 to 83

107 of the present investigation was to improve ATV bioavailability and overcome complications attendant

108 e pharmacoenhancer of the protease inhibitor ATV.

109 rveys conducted in 1997: a survey of injured ATV drivers treated in hospital emergency departments an

110 ovide important new resources to investigate ATV disease pathology and host-pathogen dynamics in natu

111 Group ATV received 27 mg/kg ATV orally, and the others received SAL 30 minutes befor

112 e performed a randomized trial of open-label ATV/r or EFV combined with abacavir/lamivudine (ABC/3TC)

113 with CKD an increasing incidence with longer ATV/r use was confirmed.

114 Upon peripheral delivery in mice, ATV:TREM2 showed improved brain biodistribution and enha

115 ripotent stem cell (iPSC)-derived microglia, ATV:TREM2 induced proliferation and improved mitochondri

116 Five micromolars ATV, within physiologic range, strongly (>95%) inhibits

117 In an AD mouse model, ATV:TREM2 boosted brain microglial activity and glucose

118 anti-Abeta) using asymmetrical Fc mutations (ATV(cisLALA)) that mitigates TfR-related liabilities and

119 nsdermal administration of nanotransfersomal ATV gel compared to oral ATV suspension.

120 ected with the radiotracer [(64)Cu]Cu-NODAGA-ATV:4D9 (ATV is antibody transport vehicle).

121 Administration of ATV(cisLALA):Abeta in mice exhibited broad brain distrib

122 ail brain region-specific biodistribution of ATV(TfR) in cynomolgus monkey brain and spinal cord.

123 ulated gene expression was characteristic of ATV.

124 The maximum achievable concentration of ATV decreased linearly as the mole fraction of ATV in th

125 promising alternative means for delivery of ATV.

126 Thus, the effects of ATV on experimental periodontitis (EP) in rats subjected

127 The effects of ATV/r and EFV upon safety and tolerability risk did not

128 played an important role in the emergence of ATV, (b) ATV bearing a Fas-resistant phenotype was a chi

129 -1 amino acid changes compared to failure of ATV/r-containing treatment.

130 V decreased linearly as the mole fraction of ATV in the formulation decreased and a similar trend was

131 r ATV clearance and higher predose levels of ATV compared to men.

132 Development and management of ATV-associated cholelithiasis are discussed.

133 ts and a survey of the general population of ATV users.

134 nificant determinants of immune selection of ATV in vivo.

135 e cohort of 388 patients, the sensitivity of ATV was 98.1% (53/54) versus 46.3% (25/54) for Affirm VP

136 The concept of ATVs has been in development for many years, and recentl

137 developing high-grade hyperbilirubinemia on ATV/r.

138 be modulated by introducing Fc mutations on ATV(CD98hc) that impact FcgammaR engagement, changing th

139 The boost effect of TVR on ATV exposure is higher than on RTV, despite its shorter

140 3TC with EFV (HR 2.46, 95% CI 1.20, 5.05) or ATV/r (HR 2.22, 95% CI 1.19, 4.14).

141 regimen modification for ABC/3TC with EFV or ATV/r and to safety events with EFV.

142 to 4 arms of ABC-3TC or TDF-FTC with EFV or ATV/r.

143 TC or TDF/FTC were not different with EFV or ATV/r.

144 an for TDF/FTC when given with either EFV or ATV/r.

145 ve ABC-3TC or TDF-FTC with open-label EFV or ATV/r.

146 and 10 each taking cART that included EFV or ATV/r.

147 ssigned (1:1) to receive EVG/COBI/FTC/TDF or ATV/RTV+FTC/TDF plus matching placebos, administered onc

148 f nanotransfersomal ATV gel compared to oral ATV suspension.

149 rides and LDL cholesterol comparable to oral ATV.

150 (-1) x d(-1)+ATV 10 mg x kg(-1) x d(-1); PIO+ATV and valdecoxib, a selective cyclooxygenase-2 (COX-2)

151 tive cyclooxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor;

152 pi-LXA4 were significantly higher in the PIO+ATV group (1.29 +/- 0.02 ng/mg; P < 0.001 versus each ot

153 th valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had

154 PIO, ATV, and their combination resulted in a small increase

155 on of 5-lipoxygenase was not altered by PIO, ATV, or their combination.

156 r in magnitude among patients receiving PIs, ATV/r, or DRV/r but lowest among those receiving RAL.

157 t receiving cART, 8 of 10 subjects receiving ATV/r, and 2 of 10 subjects receiving EFV in combination

158 iver function tests than did those receiving ATV/RTV+FTC/TDF and had smaller median increases in fast

159 periencing virologic failure while receiving ATV-containing regimens contained a unique isoleucine-to

160 More recently, ATVs targeted to C-type lectin receptors have been explo

161 itabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL

162 ith efavirenz (EFV) or atazanavir-ritonavir (ATV/r).

163 ith efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected tr

164 itabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or RAL.

165 itabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL

166 if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based combination antiretroviral therapy (cART) i

167 e, those assigned atazanavir plus ritonavir (ATV/r) did not have significantly more protease changes

168 ment responses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV) in initial antiretroviral regi

169 favirenz (EFV) or atazanavir plus ritonavir (ATV/r), on bone mineral density (BMD) have not been anal

170 or HIV is Atazanavir boosted with Ritonavir (ATV/r).

171 Dissolution of an ASD containing RTV, ATV and lopinavir (LPV) was also investigated.

172 rsion containing a 1:1:1 molar ratio of RTV, ATV and LPV, the maximum concentration of each drug was

173 A second ATV TMA assay, utilizing an alternate T. vaginalis prime

174 Women had slower ATV clearance and higher predose levels of ATV compared

175 Lastly, such ATV displayed a diminished responsiveness in their expre

176 or mechanism in the immune selection of such ATV?

177 were significantly greater with RSV LDD than ATV or placebo gels at 6 and 9 months.

178 ectrometry analysis of calculi revealed that ATV made up a median of 89% (range, 10%-100%) of the tot

179 RNA sequencing and morphometry revealed that ATV:TREM2 shifted microglia to metabolically responsive

180 mouse lung metastasis model, we showed that ATV generated either naturally in vivo or in vitro by an

181 We speculate that ATV may be especially lethal to A. mexicanum and related

182 The ATV assay was performed on remnant Aptima Combo 2 specim

183 The ATV assay was statistically more sensitive than the Affi

184 The ATV AUC(0-12), C(max), and C(min) values were 39% (13%-6

185 To test this hypothesis directly, the ATV vIF2alphaH gene (ORF 57R) was deleted by homologous

186 80% +/- 8.35%, 41.86% +/- 6.76%) than in the ATV group (25.54% +/- 8.89%, 34.31% +/- 8.04%) at 6 and

187 e of radiographic bone fill was found in the ATV group (35.49% +/- 5.50%) compared to the placebo gro

188 l CAL were seen in the RSV group than in the ATV group at 6 and 9 months.

189 uction and mean CAL gain were greater in the ATV group than the placebo group at 3, 6, and 9 months.

190 duction and mean RAL gain was greater in the ATV group than the placebo group at 3, 6, and 9 months.

191 6% in the DRV/r [P = .42]; hip: -3.9% in the ATV/r group vs -3.4% in the DRV/r group [P = .36]) but w

192 ase inhibitor (PI) arms (spine: -4.0% in the ATV/r group vs -3.6% in the DRV/r [P = .42]; hip: -3.9%

193 fore, in a biologically relevant system, the ATV vIF2alphaH gene acts as an innate immune evasion fac

194 The TVQ assay was similar to the ATV assay (kappa=0.938) in direct analysis.

195 significantly greater DDR compared with the ATV group in treatment of mandibular Class II furcation

196 To maximize their stimulatory capacity, the ATVs are being evaluated with a variety of adjuvants or

197 Thus, ATV:TREM2 represents a promising approach to improve mic

198 res (21%) among 526 participants assigned to ATV+DDI+FTC and 76 (15%) among 519 participants assigned

199 Women assigned to ATV/r had a higher risk of virologic failure with either

200 an women assigned to EFV, or men assigned to ATV/r.

201 s and 288 (23%) controls had been exposed to ATV, and 41 (10%) cases and 107 (9%) controls had been e

202 significant association between exposure to ATV (adjusted odds ratio [OR] = 1.54; 95% confidence int

203 After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidenc

204 reased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r.

205 In FHDH, exposures to ATV or to DRV were not significantly associated with the

206 EVG/COBI/FTC/TDF was non-inferior to ATV/RTV+FTC/TDF for the primary outcome (316 patients [8

207 to virologic failure in women randomized to ATV/r compared to women randomized to EFV.

208 bearing I50V revealed specific resistance to ATV and amprenavir, respectively, with no evidence of cr

209 isolates exhibiting phenotypic resistance to ATV, emerged in a variety of different backgrounds and w

210 is the signature mutation for resistance to ATV.

211 Thirty-four subjects simplified to ATV/RTV alone, of whom 30 (88%) did not experience virol

212 Subjects switched to ATV/RTV at entry and discontinued NRTIs after 6 weeks.

213 Taken together, ATV(cisLALA) has the potential to improve the next gener

214 Hologic Aptima Combo 2 (AC2) and Aptima TV (ATV), trichomonas microscopy, and culture.

215 more sensitive to interferon than wild-type ATV (wtATV).

216 f cognitive impairment in a combination (TZB+ATV) therapy.

217 The coadministration of TVR and unboosted ATV results in increased exposure of both drugs compared

218 e and after switching from ATVr to unboosted ATV (200 mg every 12 hours).

219 s of antibodies, antibody-targeted vaccines (ATV) are designed to deliver disease-specific antigens t

220 the TVQ assay, and the Aptima T. vaginalis (ATV) assay was performed using clinician-collected vagin

221 assay to the Gen-Probe Aptima T. vaginalis (ATV) transcription-mediated amplification (TMA) assay fo

222 e time select for aggressive tumor variants (ATV) in vivo?

223 injury while riding an all-terrain vehicle (ATV) are increasing.

224 determine and quantify all-terrain vehicle (ATV) risk factors.

225 ties of a CD98hc antibody transport vehicle (ATV(CD98hc)) are assessed in humanized CD98hc knock-in m

226 We developed an antibody transport vehicle (ATV) targeting transferrin receptor (TfR) for brain deli

227 ing site, termed antibody transport vehicle (ATV), to facilitate blood-brain barrier transcytosis.

228 TfR and CD98hc antibody transport vehicles (ATV(TfR) and ATV(CD98hc)) compared to control IgG.

229 (P = .024), respectively; and for EFV versus ATV/r were -1.7% and -3.1% (P = .035) and -3.1% and -3.4

230 A Tree Viewer (ATV) is a Java tool for the display and manipulation of

231 om the temperate Acidianus two-tailed virus (ATV) forms a high-affinity complex with RNAP by binding

232 m suggest that the Ambystoma tigrinum virus (ATV) eIF2alpha homologue (vIF2alphaH; open reading frame

233 ng viral pathogen, Ambystoma tigrinum virus (ATV).

234 ging consumers to dispose of the three-wheel ATVs still in use.

235 ater decreases in spine and hip BMD, whereas ATV/r led to more significant losses in spine, but not h

236 ated (353 with EVG/COBI/FTC/TDF and 355 with ATV/RTV+FTC/TDF).

237 I was noninferior to RTV in combination with ATV plus FTC/TDF at week 48.

238 l fat were found with RAL when compared with ATV/r or DRV/r over 96 weeks.

239 D-dimer declined with ATV/r and DRV/r and was unchanged with RAL.

240 of follow-up as follows: hsCRP declined with ATV/r and RAL, IL-6 declined only with RAL, and GLycA de

241 lure was similar for ABC/3TC vs TDF/FTC with ATV/r (hazard ratio [HR] 1.25, 95% confidence interval [

242 included patients admitted to hospitals with ATV-related injuries between 2002 and 2019.

243 ivity against subtype B (monotherapy or with ATV +/- RTV) and subtype C, and was generally well toler

244 n various clinical settings were tested with ATV.

245 t study, simplified maintenance therapy with ATV/RTV alone maintained viral suppression in most subje

246 Early studies with ATVs focused on the ability to induce humoral immunity i